1st Counsel – Lifestyle
Author:
Avalyn Pharma Inc.
Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors
April 6, 2026
Avalyn Announces Publication Demonstrating Correlation Between Imaging, Improved Lung Function, and Quality of Life with AP01 in Patients with Idiopathic Pulmonary Fibrosis
March 25, 2026
Avalyn Announces First Patient Dosed in AURA Phase 2 Clinical Trial Evaluating AP02, Inhaled Nintedanib, for the Treatment of Idiopathic Pulmonary Fibrosis
March 23, 2026
Avalyn Appoints Biopharmaceutical Industry Leader Kate Haviland to Board of Directors
March 5, 2026